Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Arlocabtagene Autoleucel · 1 trial · 1 indication
The number and percent of participants achieving BOR of partial response (PR) or better in quadruple class exposed participants received at least 4 prior lines of therapy (LOT)
| Arm | Type | Description |
|---|---|---|
| Arlocabtagene Autoleucel Cohort 1 | EXPERIMENTAL | - |
| Arlocabtagene Autoleucel Cohort 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Arlocabtagene Autoleucel | BIOLOGICAL | Specified dose on specified days |
Inclusion Criteria * Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria. * Received at least 4 classes of MM treatment \[including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy, and at least 3 prior li...
Top 20 of 25 competitors
Arlocabtagene Autoleucel is an investigational cell therapy being studied for the treatment of multiple myeloma. It is a GPRC5D-directed CAR T cell therapy, also known as BMS-986393, developed by Bristol-Myers Squibb. It is currently in Phase 2 clinical development for adult participants with relapsed or refractory multiple myeloma.
Arlocabtagene Autoleucel targets GPRC5D, a protein expressed on multiple myeloma cells. As a CAR T cell therapy, it is designed to direct a patient's own T cells to recognize and attack cancer cells that display GPRC5D. This mechanism is being evaluated in a Phase 2 clinical trial for relapsed or refractory multiple myeloma.
Arlocabtagene Autoleucel is being developed by Bristol-Myers Squibb Company, traded on the New York Stock Exchange under the ticker BMY. The company is conducting a Phase 2 clinical trial of this investigational CAR T cell therapy for multiple myeloma, with the study currently recruiting participants.
Arlocabtagene Autoleucel is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities. The ongoing Phase 2 trial is recruiting participants with relapsed or refractory multiple myeloma and is designed to evaluate the therapy's safety and efficacy in this patient population.
Arlocabtagene Autoleucel is being studied in a single Phase 2 clinical trial registered as NCT06297226. This study, titled 'Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma,' is currently recruiting and aims to enroll 230 participants across the United States, Australia, Canada, and Japan.
Yes, Arlocabtagene Autoleucel is also known as BMS-986393. The clinical trial NCT06297226 refers to the drug by both names, describing it as a GPRC5D-directed CAR T cell therapy. This investigational treatment is being developed by Bristol-Myers Squibb for relapsed or refractory multiple myeloma.